Liver abnormalities in bowel diseases

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 4, 2013, Pages 531-542

  Kummen, Martin ^a,b   Schrumpf, Erik ^a,b   Boberg, Kirsten Muri ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Biliary tract disease; Celiac disease; Inflammatory bowel disease; Liver disease; Primary sclerosing cholangitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AMINOTRANSFERASE; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; OLSALAZINE; PLACEBO; QUINOLONE DERIVATIVE; SALAZOSULFAPYRIDINE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URSODEOXYCHOLIC ACID;

ACUTE LIVER FAILURE; AMYLOIDOSIS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE HEPATITIS; BILIARY STENT; CELIAC DISEASE; CHOLANGIOGRAPHY; CHOLANGITIS; CHOLELITHIASIS; CHOLESTASIS; COLORECTAL CANCER; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; ENTEROPATHY; FATTY LIVER; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRANULOMATOUS HEPATITIS; HEPATITIS; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; IMMUNOGLOBULIN G4 ASSOCIATED CHOLANGITIS; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOSUPPRESSIVE TREATMENT; LIVER ABSCESS; LIVER AMYLOIDOSIS; LIVER DISEASE; LIVER GRANULOMA; LIVER HYPERPLASIA; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; PATHOPHYSIOLOGY; PELIOSIS HEPATIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; SIDE EFFECT; SINUSOIDAL DILATATION; T CELL LYMPHOMA; THROMBOEMBOLISM; TOTAL PARENTERAL NUTRITION; TOXIC HEPATITIS; ULCERATIVE COLITIS;

EID: 84885188028     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.06.013     Document Type: Review

References (100)

1. Hoffman CEE. Versehluss der Gallenwege durch Verdiekang derWandungen. Arch Pathol Anat Physiol Klin Med 1867;39: 206-15
2. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129:827-36 (Pubitemid 41242675)
3. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004;10:207-14 (Pubitemid 38618248)
4. Mendes FD, Levy C, Enders FB, Loftus EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007;102:344-50 (Pubitemid 46160549)
5. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22 (Pubitemid 32319146)
6. Rubio-Tapia A, Murray JA. The liver in celiac disease. Hepatology 2007;46:1650-8 (Pubitemid 350155546)
7. Kaukinen K, Halme L, Collin P, F?rkkil? M, M?ki M, Vehmanen P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881-8 (Pubitemid 34267270)
8. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14:331-7 (Pubitemid 351320842)
9. Olsson R, Danielsson A, J?rnerot G, Lindstr?m E, Lf L, Rolny P, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-23
10. Schrumpf E, Fausa O, Kolmannskog F, Elgjo K, Ritland S, Gjone E. Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand J Gastroenterol 1982;17:33-9 (Pubitemid 12212721)
11. Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997;32:604-10 (Pubitemid 27314273)
12. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis 2010;42:390-400
13. Freeman HJ. Hepatic manifestations of celiac disease. Clin Exp Gastroenterol 2010;3:33-9.
14. Ludvigsson JF, Elfstr?m P, Broom? U, Ekbom A, Montgomery SM. Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol 2007;5:63-9
15. Lawson A, West J, Aithal GP, Logan RFA. Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association. Aliment Pharmacol Ther 2005;21:401-5 (Pubitemid 40313942)
16. Bergquist A, Said K, Broom? U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 2007;42:88-93 (Pubitemid 46033051)
17. Sinakos E, Samuel S, Enders F, Loftus EV, Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013;19:1004-9
18. Krones E, Graziadei I, Trauner M, Fickert P. Evolving concepts in primary sclerosing cholangitis. Liver Int 2012;32: 352-69
19. Karlsen TH, Schrumpf E, Boberg KM. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2010;24:655-66
20. Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol 2013;59:571-82
21. Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, H?bscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9? gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200: 1511-7 (Pubitemid 39657298)
22. Hillan KJ, Hagler KE, MacSween RN, Ryan AM, Renz ME, Chiu HH, et al. Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver 1999;19:509-18 (Pubitemid 30019065)
23. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007;27:77-98
24. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996;110:1496-502 (Pubitemid 26134082)
25. Bergquist A, Lindberg G, Saarinen S, Broom? U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005;42:252-6 (Pubitemid 40143473)
26. Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Boberg KM, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011;53: 1977-85
27. Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670-5
28. N?ss S, Shiryaev A, Hov JR, Franke A, Karlsen TH. Genetics in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol 2012;36:325-33
29. Rausch P, Rehman A, K?nzel S, H?sler R, Ott SJ, Schreiber S, et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci U S A 2011;108: 19030-5
30. Weism?ller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis - Aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008;48(Suppl. 1):S38-57
31. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6:244-51 (Pubitemid 43290993)
32. Broom? U, Olsson R, Lf L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5 (Pubitemid 26111384)
33. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67
34. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78
35. Jorgensen KK, Grzyb K, Lundin KEA, Clausen OPF, Aamodt G, Schrumpf E, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012;18:536-45
36. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6 (Pubitemid 40007225)
37. Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981;1:632-40 (Pubitemid 12218457)
38. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VAC, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106:1638-45
39. Singh S, Khanna S, Pardi DS, Loftus EV, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:1631-8
40. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lf L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7 (Pubitemid 34194790)
41. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011; 54:1842-52
42. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006;45:568-74 (Pubitemid 44307380)
43. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451-8
44. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985;102:581-7 (Pubitemid 15120473)
45. Bj?rnsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-80 (Pubitemid 351451987)
46. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1598-619
47. Halliday JS, Djordjevic J, Lust M, Culver EL, Braden B, Travis SPL, et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis 2012;6:174-81
48. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006;101:2070-5 (Pubitemid 44337633)
49. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroidtreated autoimmune hepatitis. J Hepatol 1992;14:325-31
50. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-85
51. Volta U, Caio G, Tovoli F, de Giorgio R. Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol 2013;7:253-61
52. Sollid LM, Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol 2013;13:294-302
53. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012;590:447-58
54. Wacklin P, Kaukinen K, Tuovinen E, Collin P, Lindfors K, Partanen J, et al. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm Bowel Dis 2013;19:934-41
55. Casella G, Antonelli E, Bella CD, Villanacci V, Fanini L, Baldini V, et al. Prevalence and causes of abnormal liver function in patients with coeliac disease. Liver Int 2013;33:1128-31
56. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76
57. McGowan CE, Jones P, Long MD, Barritt AS. Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-A case series and review of the literature. Inflamm Bowel Dis 2012;18:49-54
58. Gisbert JP, Luna M, Gonz?lez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007;13:1106-14 (Pubitemid 47402594)
59. Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013;7:e279-85
60. Lapidus A, B?ngstad M, Astr?m M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol 1999;94:1261-6 (Pubitemid 29214639)
61. Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007;45:1267-74 (Pubitemid 46775790)
62. Masclee AA, Vu MK. Gallbladder motility in inflammatory bowel diseases. Dig Liver Dis 2003;35(Suppl. 3):S35-8 (Pubitemid 41070428)
63. Lapidus A, Akerlund JE, Einarsson C. Gallbladder bile composition in patients with Crohn's disease. World J Gastroenterol 2006;12:70-4 (Pubitemid 43126086)
64. Dowling RH, Bell GD, White J. Lithogenic bile in patients with ileal dysfunction. Gut 1972;13:415-20
65. Dami?o AO, Sipahi AM, Vezozzo DP, Gon?alves PL, Fukui P, Laudanna AA. Gallbladder hypokinesia in Crohn's disease. Digestion 1997;58:458-63
66. Vu MK, Gielkens HA, van Hogezand RA, van Oostayen JA, Lamers CB, Masclee AA. Gallbladder motility in Crohn disease: influence of disease localization and bowel resection. Scand J Gastroenterol 2000;35:1157-62
67. Fraquelli M, Bardella MT, Peracchi M, Cesana BM, Bianchi PA, Conte D. Gallbladder emptying and somatostatin and cholecystokinin plasma levels in celiac disease. Am J Gastroenterol 1999;94:1866-70 (Pubitemid 29315901)
68. Margalit M, Elinav H, Ilan Y, Shalit M. Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. J Gastroenterol Hepatol 2004;19:1338-42 (Pubitemid 40052850)
69. Albuquerque A, Magro F, Rodrigues S, Lopes S, Pereira P, Melo RB, et al. Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: first case report. J Crohns Colitis 2011;5:360-3
70. Andr? MFJ, Piette JC, K?m?ny JL, Ninet J, Jego P, Del?vaux I, et al. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore) 2007;86:145-61 (Pubitemid 46787969)
71. Zakout R, Fonseca M, Santos JM, Marques A, T?vora I, Oliveira E, et al. Multiple aseptic liver abscesses as the initial manifestation of Crohn's disease: report of a case. Dis Colon Rectum 2009;52:343-5
72. Stanley SL. Amoebiasis. Lancet 2003;361:1025-34
73. Sakurai T, Hajiro K, Takakuwa H, Nishi A, Aihara M, Chiba T. Liver abscess caused by Clostridium difficile. Scand J Infect Dis 2001;33:69-70 (Pubitemid 32156733)
74. Ohara Y, Kikuchi O, Goto T, Yoshida T, Mori H, Matsueda K, et al. Successful treatment of a patient with sepsis and liver abscess caused by Edwardsiella tarda. Intern Med 2012;51:2813-7
75. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657-63
76. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, et al. Thromboembolic risk among danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011;60:937-43
77. Jackson LM, O?Gorman PJ, O?Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997;90:183-8 (Pubitemid 27122556)
78. Jackson CS, Fryer J, Danese S, Vanagunas A, Polensky S, Buchman AL. Mesenteric vascular thromboembolism in inflammatory bowel disease: a single center experience. J Gastrointest Surg 2011;15:97-100
79. Maconi G, Bolzacchini E, Dell?Era A, Russo U, Ardizzone S, de Franchis R. Portal vein thrombosis in inflammatory bowel diseases: a single-center case series. J Crohns Colitis 2012;6:362-7
80. Dacha S, Devidi M, Osmundson E. Budd-Chiari syndrome in a patient with ulcerative colitis and no inherited coagulopathy. World J Hepatol 2011;3:164-9
81. Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005;100:2036-41
82. Landman C, Nahon S, Cosnes J, Bouhnik Y, Brixi-Benmansour H, Bouguen G, et al. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:582-9
83. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001;7:295-300 (Pubitemid 33062094)
84. Sattianayagam PT, Gillmore JD, Pinney JH, Gibbs SDJ, Wechalekar AD, Gilbertson J a, et al. Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci 2013;58:1689-97
85. Cabezuelo JB, Egea JP, Ramos F, Torrella E, Muray S, Alc?zar C. Infliximab in the treatment of amyloidosis secondary to Crohn's disease. Nefrologia 2012;32:385-8
86. Wang Y, Lee H, Shen B. Systemic secondary amyloidosis in a 70-year-old patient with Crohn's disease: treatment with oral budesonide. Inflamm Bowel Dis 2013;19:E74-5
87. Coash M, Forouhar F, Wu CH, Wu GY. Granulomatous liver diseases: a review. J Formos Med Assoc 2012;111:3-13
88. Jharap B, Seinen ML, de Boer NKH, van Ginkel JR, Linskens RK, Kneppelhout JC, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010;16:1541-9
89. Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013;19:1040-8
90. Gisbert JP, Gonz?lez-Lama Y, Mat? J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102:1518-27 (Pubitemid 46976279)
91. Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol 2013;53:575-88
92. B?r F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol 2013;19:1699-706
93. Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010;28: 508-18
94. Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007;56:1404-9 (Pubitemid 47517834)
95. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41
96. Jobanputra P, Amarasena R, Maggs F, Homer D, Bowman S, Rankin E, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008; 9:48
97. Logan RF, van Staa TP. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut 2003;52:536-9
98. Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-a) use for inflammatory bowel disease. Inflamm Bowel Dis 2011;17:479-84
99. Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008;121:e678-86
100. Raphael BP, Duggan C. Prevention and treatment of intestinal failure-associated liver disease in children. Semin Liver Dis 2012;32:341-7